Table 2. Detailed information about... | American Society of Hematology

Table 2.

Detailed information about patients misclassified by our predictive model

Patient ID	BCR-ABL1 % at diagnosis	BCR-ABL1 % at 3 mo	Sokal score	ELTS	BCR-ABL1 transcript type	TKIs	MMR by 12 mo	MR4.5 by 5 y	Withdrawal
EMR failure patients (n = 4) classified as low risk
145*	55	14	Int	Int	b2a2	IM	N/A	N/A	Yes
109	85	31	High	High	b3a2	IM, NIL	No	Yes	No
102	124	13	Low	Low	b3a2	IM	Yes	No	No
170	73	18	Low	Low	b3a2	IM, NIL	No	Yes	No
EMR achievement patients (n = 2) classified as high risk
183	89	1.50	Int	Int	b2a2	IM, NIL	No	No	No
159	86	6.90	High	High	b3a2	IM, NIL	No	No	No

Patient ID	BCR-ABL1 % at diagnosis	BCR-ABL1 % at 3 mo	Sokal score	ELTS	BCR-ABL1 transcript type	TKIs	MMR by 12 mo	MR4.5 by 5 y	Withdrawal
EMR failure patients (n = 4) classified as low risk
145*	55	14	Int	Int	b2a2	IM	N/A	N/A	Yes
109	85	31	High	High	b3a2	IM, NIL	No	Yes	No
102	124	13	Low	Low	b3a2	IM	Yes	No	No
170	73	18	Low	Low	b3a2	IM, NIL	No	Yes	No
EMR achievement patients (n = 2) classified as high risk
183	89	1.50	Int	Int	b2a2	IM, NIL	No	No	No
159	86	6.90	High	High	b3a2	IM, NIL	No	No	No

IM, imatinib; int, intermediate; N/A, not applicable; NIL, nilotinib.

Withdrawn at 6 months because of poor patient compliance.